Drug Delays<\/strong><\/h2>\nThe Bloomberg story<\/a> doesn’t\u200c hold back in its description:<\/p>\n
\n
Drugmakers are intentionally delaying the release of products to bypass President Joe Biden’s \u200dplan \u200dto lower medication prices<\/a>. … Companies are suspending clinical trials and shifting timelines to maximize revenue, even \u2063if it means patients have to wait longer for new therapies.<\/p>\n<\/blockquote>\n
According to the article, pharmaceutical companies have a limited \u200dwindow of time\u2063 before\u2063 the “negotiation” process begins: nine years for small-molecule pills and thirteen \u200dyears for \u2063large-molecule biologic products. Naturally, these companies are focused on maximizing revenue during this period.<\/p>\n
As a result, companies have a strong incentive to seek approval for\u2063 their drugs to treat the broadest\u200c possible condition first, even if it means delaying treatments for other medical conditions. \u2062For\u200b example, Roche may delay seeking approval for \u200da new drug to treat ovarian cancer until it gets approved for prostate cancer, potentially leaving ovarian cancer\u200d patients without a treatment option for three years.<\/p>\n
<\/div>\n
In simpler terms, this means that patients with rare diseases or conditions affecting a small number of people are likely to be the most affected by these delays.\u2062 Pharmaceutical companies will prioritize drugs that can treat millions over those that can only help\u200c a few thousand.<\/p>\n
Bloomberg also points out that while drugs treating one rare disease are exempt from price negotiations, drugs treating \u200ctwo rare diseases are not. \u200cThis discourages \u2062companies from seeking approvals for treatments for lesser-known conditions, further disadvantaging \u2063patients.<\/p>\n
These\u2062 consequences\u200b were \u200dpredictable. In\u2063 addition \u200dto the issues discussed in the Bloomberg report, a blog post in Health Affairs<\/em> highlighted the potential harm of reduced investment in long-term studies<\/a> and poorer quality medical research due\u2062 to the time constraints\u200b imposed\u200c by the “negotiation” process.<\/p>\n
<\/div>\n
It’s important to recognize \u2063that the government’s intervention in \u200bdrug pricing is the root cause of these issues. While some may criticize\u200d drugmakers for their actions, it’s crucial to understand \u2063that they are driven by financial incentives. If \u2064it\u200d becomes unprofitable to invest in\u2064 new drugs, companies may shift their \u2062focus to other projects, leaving patients with even fewer treatment options.<\/p>\n
Progressives who advocate for government control \u2062over healthcare must \u200drealize that no one is entitled to \u2063”free” new treatments. The more the government imposes price controls, the fewer innovative treatments will be \u2064developed.<\/p>\n
<\/div>\n
\t\t\t\t\t \t\t\t\t\t\t\t\t\t<\/div>\n
rnrn <\/p>\n
How are pharmaceutical companies responding to Medicare’s price controls?<\/h2>\n
The Negative Consequences of Medicare’s Price\u2063 Controls on Prescription Drugs<\/p>\n
Less than \u200c18 months after Democrats pushed through price \u2062controls \u200con Medicare’s prescription drug payments to fund\u200b subsidies for Tesla and other green initiatives, the consequences are becoming clear. Pharmaceutical companies are now responding\u2062 to these misguided incentives, resulting in delays in bringing life-enhancing and life-saving treatments<\/a> to \u200cpatients.<\/p>\n
In a recent report, Bloomberg highlighted \u200dhow drugmakers are intentionally slowing down the release of new\u200d products \u2062to maximize revenue before Medicare begins “negotiating” drug prices. This strategy ultimately harms patients who are in desperate need of innovative treatments.<\/p>\n
The Bloomberg \u200bstory doesn’t hold back\u200d in its description: “Drugmakers are\u200d intentionally delaying the release of products to bypass President Joe\u200d Biden’s plan \u2062to lower medication prices. … Companies\u200d are suspending clinical trials \u200dand shifting timelines to maximize\u2062 revenue, even if it means \u2064patients have to \u200cwait longer\u2064 for new\u200c therapies.”<\/p>\n
According to\u200d the article, pharmaceutical companies \u200bhave a limited window of time before the \u2063”negotiation” process begins: nine years for \u2062small-molecule\u200d pills and thirteen years for \u2062large-molecule biologic products. Naturally, these \u200dcompanies are focused on maximizing revenue during this period.<\/p>\n
As a \u2062result, companies have a strong incentive to seek approval for \u200ctheir\u200d drugs to treat the broadest possible condition first, even if it \u2063means delaying\u200c treatments for other medical\u200c conditions. For example, Roche may delay\u2064 seeking approval for \u200ca new drug to treat ovarian cancer until it gets approved \u200bfor prostate cancer, potentially leaving\u2064 ovarian cancer patients without a treatment option for three years.<\/p>\n
This kind of prioritization based \u200don profitability rather than patient need\u2062 is a direct consequence of the price controls imposed by Democrats.\u2062 By\u2062 limiting the financial rewards for developing \u200cand bringing new drugs to market, the government has inadvertently\u2064 created\u2064 a disincentive for pharmaceutical companies to pursue treatments for less common or niche \u2063medical conditions.<\/p>\n
Innovation \u200bin \u200dthe pharmaceutical industry is driven\u200d by the promise of\u2064 financial gain. Without the ability to recoup their investments and generate profits, companies have less motivation to \u2064engage in research and development that may yield groundbreaking treatments for patients.<\/p>\n
Moreover, these delays in the release of new drugs limit the options available to healthcare\u200c professionals, leaving \u2063them with fewer tools to address the diverse needs of their patients.<\/p>\n
It is important to recognize that while price \u2064controls may seem like \u2063a quick fix to lower drug prices,\u200c they\u2064 have far-reaching and unintended consequences. By impeding the development \u2064and release of innovative treatments, they ultimately harm the very \u2062patients they aim to help.<\/p>\n
In order \u200cto ensure\u2063 timely access to life-enhancing and life-saving treatments, policymakers should consider alternative\u200c solutions that encourage \u2064pharmaceutical innovation while addressing the affordability of medication for \u200bpatients. This could involve implementing reforms that promote competition, increase transparency in pricing, and\u2064 incentivize the development of new drugs through patent simplification and regulatory flexibility.<\/p>\n
In conclusion, the consequences of Medicare’s price controls on prescription drugs are becoming clear. \u2062Delays in\u2064 the release \u2062of new treatments due to pharmaceutical companies prioritizing revenue generation over patient needs are a direct result of these policies. It is essential for policymakers to \u2063reevaluate their approach and seek alternative solutions that balance affordability with innovation, ensuring that patients have \u200ctimely access to the treatments they need.<\/p>\n","protected":false},"excerpt":{"rendered":"
In under 18 months, Democrats enforced price controls on Medicare’s prescription drug payments to fund Tesla subsidies and green projects. As a result, drug manufacturers are now reacting to these unfavorable incentives. Bloomberg recently highlighted this issue right before the holiday season<\/p>\n","protected":false},"author":521,"featured_media":2146199,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[],"tags":[],"class_list":["post-2146198","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2146198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/521"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2146198"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2146198\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2146199"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2146198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2146198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2146198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

How are pharmaceutical companies responding to Medicare’s price controls?<\/h2>\n The Negative Consequences of Medicare’s Price\u2063 Controls on Prescription Drugs<\/p>\n